MSA Therapy Verdiperstat Fails to Meet Primary End Point in Phase 3 Trial
The agent had previously demonstrated positive results in a phase 2a setting, with favorable trends on modified Unified MSA Rating Scale scores across a 12-week period.
Irfan Qureshi, MD
Verdiperstat, Biohaven’s investigational first-in-class potent, selective, brain-penetrant, irreversible myeloperoxidase (MPO) enzyme inhibitor, failed to statistically differentiate from placebo on prespecified primary efficacy measures in the phase 3 M-STAR clinical trial (NCT03952806) of patients with multiple system atrophy (MSA). The company noted that additional analyses are still pending, with full results expected to be presented at an upcoming scientific meeting.1
A total of 250 patients, aged 40 to 80 years, with MSA were randomized 1:1:1 to verdiperstat 300 mg or 600 mg twice daily or placebo in the double-blind, parallel-group study. The primary efficacy end point was the change from baseline to week 48 on modified Unified MSA Rating Scale (UMSARS) score, which consists of a subset of items from the UMSARS Part I (Activities of Daily Living) and Part II (Motor Exam) that directly assessed clinically meaningful change in patients’ ability to function.
"While we are disappointed that verdiperstat did not demonstrate efficacy for the treatment of MSA, Biohaven remains committed to fighting on behalf of people living with neurodegenerative diseases. There are currently no approved disease-modifying therapies for MSA and we must continue to advance the science to improve treatment outcomes for patients suffering from this disease,” Irfan Qureshi, MD, vice president, Neurology, Biohaven, said in a statement.1 “We are extremely grateful to the international MSA community—especially the patients and their families, investigators and their teams, and patient advocacy groups—who made the trial possible."
READ MORE: NeuroVoices: David R. Lynch, MD, PhD, on the First Potentially Approved Friedreich Ataxia Treatment
The therapy was designed as a unique orally administered MPO inhibitor, as the MPO enzyme acts as a key driver of oxidative stress and inflammation that underlies neurodegeneration and is abundant in activated microglial cells found in the brains of patients with MSA. The history of the drug has been well documented with the FDA as it moved through the clinical pipeline. In February 2019, the agent received orphan drug designation after completing its phase 1 and 2a clinical trials.2
The 12-week, randomized, double-blind, placebo-controlled phase 2a study (NCT02388295) designed to evaluate the safety and tolerability of 300- and 600-mg verdiperstat demonstrated that the drug significantly decreased MPO activity in plasma, with favorable trends over 12 weeks on UMSARS. Over the treatment period, patients in the placebo group experienced greater worsening on the UMSARS, with a 4.6-point decline (standard error [SE], 1.1 [90% CI, 2.5-6.8]) compared with 3.7- (SE, 1.2 [90% CI, 1.4-5.7]) and 2.6-point (SE, 1.4 [90%, 0.5-4.7]) declines in patients treated with verdiperstat 300 mg or 600 mg, respectively.2
Verdiperstat is currently also being tested in the Healey-ALS trial, the world’s first platform study evaluating multiple drugs in patients with amyotrophic lateral sclerosis (ALS). Started in March 2020, the ongoing trial will use a combination of verdiperstat, zilucoplan, and nanocrystalline gold, and aims to find results using the ALS Functional Rating Scale-Revised as a primary end point. That trial is expected to conclude in March 2022.1
